Kyle Picha's avatar
$2.5m follower assets
Stock Review: $ZYXI
  • I’m now watching this one closely. If the market wasn’t in a bad downtrend, I’d buy this stock rn.
  • Their Q1 22’ report beat Q1 21’ in revenue, net income, and EPS. Meaning their FY 22’ is on track to beat FY 21’ in all 3 categories.
  • CEO gave great FY 2022 guidance.
  • Announced Share Buyback Program up to $10M over next 12 months.
2020: $80.1M
2021: $130.3M
2022: $150M - $170M (guidance)
2020: $9.1M
2021: $17.1M
2022: on track to beat 2021
2020: 0.24
2021: 0.41
2022: on track to beat 2021
$256.9M. Small cap. Lots of room for rapid stock price (and overall company) growth.
From CEO: “March saw the largest number of orders in the Company's history, and we are expecting continued growth throughout all of 2022. We recently announced a stock buyback program of up to $10 million over the next 12 months to signal our confidence in the Company's long-term strategy. We believe that the decision will ultimately drive shareholder value and have already repurchased approximately $5 million from April 12th through April 27th, 2022.
Full year 2022 revenue is estimated in the range of $150-$170 million and Adjusted EBITDA between $25 and $35 million. Profitability is expected to grow as sales reps become more efficient, further highlighting the anticipated EBITDA growth in 2022.
The estimated range for second quarter 2022 revenue is between $35.0 and $38.0 million, an increase of approximately 18% from 2Q21.
Second quarter 2022 Adjusted EBITDA is estimated to range between $4.0 and $6.0 million, an increase of approximately 5% from 2Q21.
Zynex, Inc is an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring.
No. I could not locate any external factor that alone heavily affects their earnings.
Price has increased from $0.27 to $6.58 since Dec 2016.
To hear about more high-potential stocks EARLY, long before they produce life-changing returns.
Yegor From100Kto1M's avatar
I wouldn’t call $ZYXI innovative, they sell cheap tens units to medicare patients and sometimes over bill

There been a few shorts on it’s tails and I think for a good reason

I would be very careful with this one
Kyle Picha's avatar
@from100kto1m I agree, just took a lot of the description off their website lol however, a good reason they have shorts now is because their stock price appreciated over 100x between 2016-2020. That’s incredibly fast appreciation, almost too fast really. All we know right now is that the company is growing consistently so let’s see if they can keep it up. I bet if they keep up this growth for the next 5-10 years, their stock price will appreciate tremendously from here. Not in the short term tho, the market is trash and we don’t know how long that’ll last
Conor Mac's avatar
Love how these reviews are getting longer and better quality over time. Also nearly 100 followers, woo!
Kyle Picha's avatar
@investmenttalk appreciate that man! I’m hoping to get better & better with each 😎